Replimune Appoints Tanya Lewis to the Board of Directors
October 19 2020 - 4:01PM
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company
developing oncolytic immuno-gene therapies derived from its
Immulytic™ platform, today announced the appointment of Tanya Lewis
to its Board of Directors, effective as of November 2, 2020.
“Tanya is a respected and highly accomplished pharmaceutical
industry executive with greater than 20 years of experience in
global drug development across a variety of therapeutic areas,
including oncology,” said Philip Astley-Sparke, CEO of Replimune.
“It is my pleasure to welcome Tanya to our board. In particular,
Tanya adds deep expertise in developing and executing regulatory
strategies and we look forward to her contributions as we plan to
bring our leading pipeline of oncolytic immunotherapies to
market.”
Ms. Lewis currently serves as the Executive Vice President,
Chief Regulatory Strategy and Strategic Operations at Karyopharm
Therapeutics, a publicly-traded biopharmaceutical company (Nasdaq:
KPTI) where she navigated the approval of XPOVIO®. Prior to joining
Karyopharm, Ms. Lewis held leadership positions at several
companies, including Tesaro and Millennium, where she developed
approval strategies and led interactions with U.S. and European
regulators for clinical trial applications, marketing applications
(including ODAC presentations) and drug labeling. Tanya’s past
accomplishments include the successful negotiations for
registration trial designs, approval, and/or commercialization of
VELCADE®, VARUBI®, INTEGRILIN® and ZEJULA®.
Tanya holds a Bachelor of Science degree in Biology from
Northeastern University and a Master of Science degree in
Regulatory Affairs and Public Health from Massachusetts College of
Pharmacy and Allied Health Science.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded
in 2015 to develop the next generation of oncolytic immune-gene
therapies for the treatment of cancer. Replimune is developing
novel, proprietary therapeutics intended to improve the direct
cancer-killing effects of selective virus replication and the
potency of the immune response to the tumor antigens released.
Replimune’s Immulytic™ platform is designed to maximize systemic
immune activation, in particular to tumor neoantigens, through
robust viral-mediated immunogenic tumor cell killing and the
delivery of optimal combinations of immune-activating proteins to
the tumor and draining lymph nodes. The approach is expected to be
highly synergistic with immune checkpoint blockade and other
approaches to cancer treatment across a broad range of cancers.
Replimune intends to progress these therapies rapidly through
clinical development in combination with other immuno-oncology
products with complementary mechanisms of action. For more
information, please visit www.replimune.com.
Forward Looking Statements
This press release contains forward looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding our expectations about our
plans to commercialize our product candidates, and other statements
identified by words such as “could,” “expects,” “intends,” “may,”
“plans,” “potential,” “should,” “will,” “would,” or similar
expressions and the negatives of those terms. Forward-looking
statements are not promises or guarantees of future performance,
and are subject to a variety of risks and uncertainties, many of
which are beyond our control, and which could cause actual results
to differ materially from those contemplated in such
forward-looking statements. These factors include risks related to
our limited operating history, our ability to generate positive
clinical trial results for our product candidates, the costs and
timing of operating our in-house manufacturing facility, the timing
and scope of regulatory approvals, changes in laws and regulations
to which we are subject, competitive pressures, our ability to
identify additional product candidates, political and global macro
factors including the impact of the coronavirus as a global
pandemic and related public health issues, and other risks as may
be detailed from time to time in our Annual Reports on Form 10-K
and Quarterly Reports on Form 10-Q and other reports we file with
the Securities and Exchange Commission. Our actual results could
differ materially from the results described in or implied by such
forward-looking statements. Forward-looking statements speak only
as of the date hereof, and, except as required by law, we undertake
no obligation to update or revise these forward-looking
statements.
Investor Inquiries Chris BrinzeyWestwicke, an
ICR Company339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen Goldenberg Verge
Scientific
Communications917.548.1582agoldenberg@vergescientific.com
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Sep 2023 to Sep 2024